摘要
目的观察甘精胰岛素联合瑞格列奈治疗2型糖尿病的临床疗效及安全性分析。方法选择138例符合本次研究标准的患者,随机分为对照组和治疗组均68例,两组患者均停止服用之前的降糖药物,在饮食、运动及心理治疗的基础上,对照组给予精蛋白生物合成人胰岛素30R(诺和灵30R),分早、晚2次餐前30分钟皮下注射;治疗组给予甘精胰岛素(来得时),每晚22:00皮下注射,1次/d,瑞格列奈片(诺和龙),起始剂量0.5～1mg,3次/d,餐前20min口服,两组均治疗12周。结果治疗组低血糖发生率明显低于对照组(P<0.05);两组治疗后与治疗前在FBG、2hPG、HbA1C比较,均有明显下降(P<0.01),治疗后治疗组与对照组组间在FBG比较,无明显差异(P>0.05),治疗后两组组间在2hPG、HbA1C比较,治疗组明显优于对照组(P<0.05或0.01)。结论甘精胰岛素联合瑞格列奈治疗2型糖尿病疗效确切,低血糖发生率低,安全性高。
Objective To observe the clinical efficacy and safety analysis of insulin glargine joint repaglinide of treating type 2 diabetes. Methods 138 patients with type 2 diabetes who were randomly divided into two groups,the control group and the treatment group were 68 cases,patients in both groups stop taking hypoglycemic drugs before,on the basis of the diet,exercise and psychotherapy.The control group were given protamine biosynthetic human insulin 30 R（Novolin 30 R）points early,late 2 times 30 minutes before a meal subcutaneous injection;The treatment group received insulin glargine （Lantus）,22：00 subcutaneous injection,1 time a day, repaglinide tablets（repaglinide）,the initial dose of 0.5-1 mg,3 times a day, before a meal 20minute oral,both groups were treated for 12 weeks. Results After treatment,the incidence of hypoglycemia was significantly lower than the control group（P 〈 0.05）; 2 groups after treatment and before treatment in FBG 2hPG,HbA1C comparison,were significantly reduced （P 〈 0.01）;After treatment the treatment group and the control groups in FBG was no significant difference（P 〉 0.05）,After the treatment,compared with the two groups in 2hPG,HbA1C,the treatment group was significantly better than the control group（P 〈 0.05 or 0.01）. Conclusion The insulin glargine United repaglinide had clear efficacy,low incidence of hypoglycemia and high security in treatment of type 2 diabetes.
出处
《中国医药科学》
2013年第4期66-67,共2页
China Medicine And Pharmacy
